分组1 - Sinopec announced a cash dividend of RMB 0.088 per share (tax included) for the first half of 2025, with a total cash dividend distribution of RMB 10.662 billion [3] - Guokai Microelectronics is progressing with the acquisition of a 94.366% stake in Zhongxin Integrated Circuit (Ningbo) Co., Ltd. through a combination of share issuance and cash payment [4] - Phoenix Shipping's Vice President Zhao Qiuling resigned due to work adjustments, while Wang Guozheng was appointed as the new CFO [5] 分组2 - Guokai Microelectronics is actively advancing its major asset restructuring, with due diligence and evaluation processes underway [4] - The stock name of Guokai Co., Ltd. will change to Guokai Electronics starting September 11, 2025 [6] - Xinhua Pharmaceutical's Vice President Zheng Zhonghui resigned for personal reasons, holding 397,600 shares in the company [7] 分组3 - Unified Holdings completed the change in the shareholding structure of its controlling shareholder, with the actual controller changing from the Ministry of Finance to Central Huijin Investment [8] - ST New Power's stock may face delisting risk warnings due to a negative audit opinion on its internal controls for the 2024 financial report [9] - Huachuang Yuxin announced that 1.87% of its shares held by Shanghai Shiran Industrial Co., Ltd. will be auctioned [10] 分组4 - Zhengbang Technology's subsidiary Chaoyang Zhengbang has been accepted for reorganization by the court, with total assets of RMB 332 million and liabilities of RMB 460 million as of December 31, 2024 [11] - China Shipbuilding Defense's General Manager Chen Liping resigned due to work changes [12] 分组5 - Poly Developments reported a signing amount of RMB 18.015 billion in August 2025, a year-on-year decrease of 18.54% [14] - Muyuan Foods reported sales revenue of RMB 11.85 billion from selling 7.001 million pigs in August 2025, with a year-on-year decrease of 12.30% [15] - Dongrui Co., Ltd. reported a sales revenue of RMB 160 million from selling 94,800 pigs in August 2025, a month-on-month decrease of 5.48% [16] 分组6 - Ankai Bus reported a cumulative production increase of 68.06% year-on-year, with a total production of 5,625 vehicles in 2025 [17] - Kangchen Pharmaceutical's controlling shareholder Liu Jianhua plans to reduce his stake by up to 3% [19] - Kewell plans to reduce its shares by up to 2.34% [20] 分组7 - North Special Technology plans to raise no more than RMB 300 million through a private placement for a production base project in Thailand [29] - Guangqi Technology signed contracts worth RMB 1.278 billion for the mass production of metamaterials [31][32]

Group 1 - Huaneng Power announced that its shareholder Hunan Energy Group plans to reduce its stake by up to 20.31 million shares, not exceeding 1% of the total share capital [1] - Ankai Bus reported a production of 1,012 buses in August, a year-on-year increase of 68.06%, with sales of 773 buses, up 46.95% year-on-year [1] - Lianhuan Pharmaceutical received a drug registration certificate for Famotidine injection, classified as a Class 3 chemical drug [1][2] Group 2 - Dongrui Co. reported sales of 94,800 pigs in August, generating revenue of 160 million yuan, a month-on-month decrease of 5.48% [3] - Tiancheng Control's subsidiary received a notification for a passenger car seat assembly project, expected to start production in April 2026 [5] - ST Huluwa obtained a drug registration certificate for Cefodizime capsules, a third-generation broad-spectrum cephalosporin [6] Group 3 - Jiulong Biotech announced the resignation of its Vice Chairman and General Manager Liang Hongjun due to work adjustments [8] - Guanhua High-tech's shareholder plans to reduce its stake by up to 17.50 million shares, not exceeding 1% of the total share capital [9] - Hebei Steel received approval to issue bonds totaling up to 10 billion yuan [10] Group 4 - Yunnan Energy Investment's subsidiaries received a total of 309 million yuan in renewable energy price subsidies [12] - Zhenghong Technology reported sales of 16,800 pigs in August, with a revenue of 22.87 million yuan, showing a year-on-year increase in sales volume of 63.31% [14] - Jilin Aodong's subsidiary received a drug registration certificate for a solution used in asthma treatment [16] Group 5 - Aonong Biological reported a 26.84% year-on-year increase in pig sales volume in August, reaching 150,100 pigs [18] - Xingdesheng announced a share repurchase plan with a budget of 15 to 30 million yuan [20] - Yueyang Lin Paper's Chairman Ye Meng resigned due to work adjustments [22] Group 6 - Kangchen Pharmaceutical's controlling shareholder plans to reduce its stake by up to 4.78 million shares, not exceeding 3% of the total share capital [23] - Changchun Yidong's General Manager Liu Xiaodong resigned due to work adjustments [25] - Zhongzai Resources' subsidiary received a government subsidy of 12.75 million yuan [26] Group 7 - Tianyu Biological reported a 41.89% month-on-month increase in sales revenue from pig sales in August [27] - Changfei Optical's shareholder Draka Comteq B.V. reduced its stake from 10% to 5% [27] - Zhongchuan Technology's Chairman Wu Xingwang resigned due to work adjustments [28] Group 8 - Huakang Clean announced a successful bid for a medical service construction project valued at 131 million yuan [29] - Yuegui Co. plans to establish a wholly-owned subsidiary with a registered capital of 100 million yuan [31] - Baisheng Intelligent's Vice General Manager and Board Secretary Huang Lijun resigned for personal reasons [32] Group 9 - Jiangsu Shuntian will change its stock name to "Suhao Fashion" starting September 10, 2025 [34] - Jiahe Meikang's shareholder plans to reduce its stake by up to 1.3759 million shares, not exceeding 1% of the total share capital [35] - Heng Rui Pharmaceutical received approval for clinical trials of HRS-4729 injection [37] Group 10 - Changfei Optical's shareholder plans to reduce its stake by up to 110,000 shares, not exceeding 0.15% of the total share capital [39] - Yutong Bus reported sales of 4,260 vehicles in August, a year-on-year increase of 16.78% [40] - JinkoSolar received 646 million yuan in renewable energy subsidies in August, a 248% increase year-on-year [41] Group 11 - Beijing Lier signed a strategic cooperation agreement with SenseTime and Xiwang Technology for AI collaboration [43] - Gongdong Medical's controlling shareholder plans to reduce its stake by up to 3% [44] - Zhonghuan Hailu terminated its control change plan and resumed trading [46] Group 12 - Longzi Co. reported a tax payment of 22.27 million yuan due to a tax audit [48] - Guoguang Chain's controlling shareholder plans to reduce its stake by up to 2.99% [49] - Guoxin Technology successfully tested a new high-performance chip for automotive electronics [50] Group 13 - GF Securities reported a cumulative increase in borrowings exceeding 20% of its net assets [51] - China Construction Bank's subsidiary plans to increase capital by 3 billion yuan [52] - Jifeng Technology plans to establish a wholly-owned subsidiary with a capital of 50 million yuan [53] Group 14 - Jiantou Energy received approval for a stock issuance plan to specific investors [54] - Shanghai Laishi's executives plan to collectively increase their holdings by at least 6 million yuan [55] - Wencan Co. reported a fire incident at its subsidiary, with no casualties reported [56]

Core Points - 康辰药业's controlling shareholder, Liu Jianhua, plans to reduce his stake in the company by up to 4.7807 million shares, which represents no more than 3% of the total shares [1] Summary by Category Shareholder Actions - Liu Jianhua intends to sell shares through centralized bidding and block trading methods within three months after a 15 trading day period from the announcement date, excluding any legally mandated holding periods [1]

Core Viewpoint - The major shareholder of Beijing Kangchen Pharmaceutical Co., Ltd., Liu Jianhua, plans to reduce his shareholding due to personal financial needs, with a maximum reduction of 4,780,693 shares, which is approximately 3% of the total share capital [1][2]. Shareholder Reduction Plan - Liu Jianhua holds 50,786,760 shares, representing 31.87% of the total share capital of 159,356,477 shares as of September 5, 2025 [1][2]. - The reduction will occur within three months starting from 15 trading days after the announcement, specifically from September 29, 2025, to December 28, 2025 [2]. - The reduction methods include centralized bidding and block trading, with a maximum of 1,593,564 shares through centralized bidding and 3,187,129 shares through block trading [2]. - The reduction price will be based on the market price at the time of the reduction [1]. Compliance and Previous Commitments - Liu Jianhua previously committed to not reducing his shareholding below the issue price for two years after the lock-up period, with a maximum cumulative reduction of 20% of his total shares [3]. - The current reduction plan is consistent with the commitments made in the company's initial public offering (IPO) prospectus [3]. Regulatory Compliance - The reduction plan complies with relevant laws and regulations, including the Company Law and Securities Law of the People's Republic of China [3]. - The company will continue to monitor the situation and fulfill its information disclosure obligations as required [3].

智通财经APP讯，康辰药业(603590.SH)发布公告，自公告披露之日起15个交易日后的3个月内(根据法律 法规禁止减持的期间除外)，公司控股股东刘建华先生因自身资金需求拟通过集中竞价、大宗交易方式 减持其所持有的公司股份，合计不超过478.07万股，即不超过规定的公司股份总数的3%。 （原标题：康辰药业(603590.SH)控股股东拟减持不超3%股份） ...

（文章来源：每日经济新闻） 9月5日，康辰药业公告，公司控股股东刘建华先生计划在2025年9月29日至2025年12月28日期间，通过 集中竞价和大宗交易方式减持不超过478.07万股，占公司总股本的3%。减持原因是自身资金需求。减 持价格将根据市场情况确定。减持计划的实施存在不确定性，具体取决于市场情况、自身实际情况及监 管部门政策变化等因素。 ...

Core Viewpoint - Kangchen Pharmaceutical announced a share reduction plan by its controlling shareholder Liu Jianhua due to personal funding needs, which may impact the company's stock performance [1] Summary by Relevant Sections - **Share Reduction Plan** - Liu Jianhua plans to reduce his holdings by up to 4.7807 million shares, representing no more than 3% of the company's total share capital [1] - The reduction will occur within three months starting from 15 trading days after the announcement [1] - **Method of Reduction** - The share reduction will be executed through both centralized bidding and block trading methods [1] - Up to 1.5936 million shares will be sold via centralized bidding, while up to 3.1871 million shares will be sold through block trading [1] - **Pricing and Uncertainty** - The selling price will be determined based on the market price at the time of the reduction [1] - The implementation of this reduction plan carries uncertainty [1]

Group 1 - The core point of the article is that Kangchen Pharmaceutical's innovative drug KC1036 has been included in the "Children's Antitumor Drug Research and Development Encouragement Pilot Program (Starlight Program)" by the National Medical Products Administration [1] - The company will actively report progress or results related to the implementation framework required by the drug review center to jointly promote the clinical development and market launch of KC1036 in the field of pediatric Ewing's sarcoma [1] - Additionally, the company's controlling shareholder, Liu Jianhua, plans to reduce his holdings by a total of no more than 4.7807 million shares, which is not more than 3% of the company's total shares, through centralized bidding and block trading [1]

证券代码：603590 证券简称：康辰药业 公告编号：临 2025-051 北京康辰药业股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、减持主体的基本情况 1 | | 其他：/ | | --- | --- | | 持股数量 | 50,786,760股 | | 持股比例 | 31.87% | | 当前持股股份来源 | IPO 前取得：50,786,760股 | 上述减持主体存在一致行动人： 重要内容提示： 大股东持股的基本情况 本次减持计划实施前，北京康辰药业股份有限公司（以下简称"公司"）控 股股东刘建华先生持有公司股份 50,786,760 股，占公司总股本的 31.87%（以公 司截至 2025 年 9 月 5 日总股本即 159,356,477 股为基数计算，下同）。 减持计划的主要内容 自本公告披露之日起 15 个交易日后的 3 个月内（根据法律法规禁止减持的 期间除外），刘建华先生因自身资金需求拟通过集中竞价、大宗交易方式减持其 所持有的公司股份，合计不超过 4,78 ...

证券代码：603590 证券简称：康辰药业 公告编号：临 2025-052 由药审中心组织制定的"儿童抗肿瘤药物研发鼓励试点计划（星光计划）"， 主要为贯彻落实国家药监局"提前介入、一企一策、全程指导、研审联动"的要求， 加强与申请人的沟通交流，就抗肿瘤药物儿童人群研究过程中技术难点提供针对性 指导，提高儿童抗肿瘤药物的研发效率。 本次公司 KC1036 作为首批首个入选"星光计划"的创新药品种，代表药审中 心对 KC1036 创新性和在青少年尤文肉瘤患者获益性上的认可，更推动公司关注中 北京康辰药业股份有限公司 关于 KC1036 纳入药审中心"星光计划"试点项目的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，北京康辰药业股份有限公司（以下简称"公司"）1 类创新药 KC1036 被国家药品监督管理局药品审评中心（以下简称"药审中心"）纳入"儿童抗肿瘤 药物研发鼓励试点计划（星光计划）"。现将主要情况公告如下： 一、药品相关情况 KC1036 是公司自主研发的化学药品 1 类创新药，公司拥有该产品的全球知识 产 ...